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with the consistency of the test [5, 6] . Therefore, several studies have analysed the value of other antibody markers for prediction of IDDM.
It has been shown that the prediction of IDDM can be considerably improved by the addition of insulin autoantibodies (IAA), autoantibodies to glutamic acid decarboxylase (GADA) and autoantibodies to 37 kDa (37 kDa-ab) and 40 kDa (40 kDa-ab) antigens in ICA positive individuals [7] [8] [9] [10] [11] [12] . Primary screening for either IAA or GADA alone, however, has proved to be less specific than ICA testing [7, [13] [14] [15] . In contrast, 37 kDa-ab and 40 kDa-ab have been reported to be strongly associated with rapid progression to IDDM, but like other markers these antibodies are unable to identify all individuals who later develop IDDM [4, 11] . Due to the labour intensive test procedure using radiolabelled islet cells, it has been difficult to screen large numbers for 37 kDa-ab/40 kDaab so far [16] . Recently, Christie and co-workers [16, 17] identified the 40 kDa antigen as the intracytoplasmic domain of the tyrosine phosphatase IA-2 (IA-2 ic) [17, 18] . With the cloning of the human IA-2 cDNA, population-based screening for autoantibodies to IA-2 is now possible. In this study we describe a radiobinding assay which allows quantitative measurement of autoantibodies to IA-2 ic (anti-IA-2 ic) on a large scale. We also show population-based data on the prevalence of IA-2 antibodies and demonstrate that combined screening for anti-IA-2 ic and GADA identify almost all subjects with high levels of ICA in first degree relatives of patients with IDDM. These data suggest that screening for antibodies to IA-2 in combination with GADA may represent a powerful strategy for routine screening to identify subjects at increased risk for IDDM.
Subjects and methods
Patients. Sera were obtained from the first sample of 1238 nondiabetic first degree relatives of IDDM patients (663 females, 575 males; age 0.1 and 57 years, mean age 12.7 ± 11.6 years), who were recruited by the screening programme of the Deutsche Nikotinamid Interventions-Studie (DENIS). Sera of probands participating in the DENIS Study were collected before the start of study treatment. Sera from 100 healthy individuals (mean age 16.5 years, range 7-28 years) without a family history of IDDM were used as controls. Informed consent was obtained from the subjects or their parents. The study was approved by the ethical committees of the centres participating in the study.
Detection of autoantibodies to human recombinant GAD 65
and IA-2. Autoantibodies to the intracytoplasmic domain of IA-2 (anti-IA-2 ic) and GADA were determined using radiolabelled human recombinant antigens in a 96-well assay format. Recombinant autoantigens were produced by coupled in vitro transcription and translation (Promega, Madison, Wis., USA) of human IA-2 ic cDNA, coding for IA-2 ic (amino acids 603-980) [17] and human GAD 65 cDNA (a kind gift of Å . Lernmark, Seattle, USA) [19] , respectively.
Plasmid cDNA (1 m g) coding either for GAD 65 or IA-2 ic was incubated with the reticulocyte lysate system and 35 S methionine (10 mCi/ml, > 1000 Ci/mmol; Amersham Ltd., Amersham, Bucks., UK) according to the manufacturer's instructions. Incorporation of radioactivity in recombinant proteins was monitored by precipitation with trichloroacetic acid. We incubated 10,000 cpm of in vitro synthesized IA-2 ic, or 20 m l) and precipitates were punched out into 5 ml scintillation vials (Multiple 8-punch system; Millipore) to count bound proteins in a liquid scintillation counter. Alternatively, immunoprecipitates were subjected to SDS-PAGE and analysed by autoradiography. In each experiment the same positive and negative standard sera were included in duplicates. Antibody levels were expressed as arbitrary units (AU) calculated as follows: U = (cpm[test serum] -cpm[negative standard serum]) / (cpm[positive standard serum] -cpm(negative standard serum]) × 100. Intra-assay and inter-assay coefficients of variation of the IA-2 ic antibody assay were 7.7 % (n = 9) and 10.9 % (n = 9), respectively. To achieve high specificity of antibody detection the cut off for antibody positivity was set at mean + 4 SD of antibody levels in 100 normal control sera (7 GAD-U and 3 IA-2-U). In the Second GAD Antibody Proficiency Program our GADA assay achieved 100 % sensitivity and 100 % specificity.
Detection of cytoplasmic ICA. Islet cell antibodies were detected by the indirect immunofluorescence test on unfixed cryostat sections of human pancreas from an organ donor with blood group 0 as described [20] . Determinations were carried out on the same tissue and the results were expressed in Juvenile Diabetes Foundation JDF units according to the workshop protocol for the standardisation of ICA. The detection limit of the assay in our laboratory was 3 JDF-U. In the 10 th International Diabetes Workshop ICA Proficiency Program our laboratory achieved values of 90 % for sensitivity and 100 % for specificity (Laboratory identification No 298).
Statistical analysis
The significance of differences between observations was tested using the Wilcoxon test, the chi-square test with Yates' correction, Fisher's exact test, or Mann-Whitney test where appropriate. The significance of correlations between antibodies was tested by Spearman rank correlation analysis.
Results
Prevalence of autoantibodies. Among 1238 non-diabetic first degree relatives of patients with IDDM 54 (4.4 %) were positive for anti-IA-2 ic (mean age 10.5 ± 9.9 years, 26 females, 28 males), 78 (6.3 %) had GADA (mean age 11.0 ± 8.9 years, 35 females, 43 males) and 86 (6.9 %) were ICA positive (mean age 11.4 ± 8.8 years, 39 females, 47 males). Only 1 of 100 (1.0 %) normal control subjects had GADA (range 0-9.0 GAD-U), and none of 100 individuals were positive for anti-IA-2 ic (range 0-2.8 IA-2 ic-U) or ICA (p < 0.05) ( Table 1) . Of these subjects 33 (2.7 %) were positive for only one test, while 37 (3.0 %) subjects had two markers and 37 (3.0 %) subjects were found positive for all three markers, i. e. ICA, anti-IA-2 ic and GADA. There was no significant association of any antibody with age or gender.
Association between IA-2 ic antibodies, GADA and ICA. The distribution of the three antibody specificities within the study population is illustrated in Figure 1 . Both anti-IA-2 ic as well as GADA were positively associated with the presence of ICA. IA-2 ic antibodies were detected in 51 (59.3 %) and GADA in 59 (68.6 %) of 86 ICA positive subjects, respectively (p < 0.0001) (Fig. 1) . Significantly higher frequencies of anti-IA-2 ic and GADA were found in subjects with ICA levels of 20 JDF-U or more (42/ 63 [66. (Fig. 2) . As illustrated in Figure 2 only 3 of 1152 (0.26 %) ICA negative relatives had anti-IA-2 ic. In one of these three cases high levels of GADA (80.2 GAD-U) were also detected. Out of 35 ICA positive anti-IA-2 ic negative sera 22 (62.9 %) were found to be positive for additional GADA. GADA in the absence of ICA and anti-IA-2 ic were observed in 18 of 78 (23.1 %, 1.5 % of the total population) GADA positive subjects, which is similar to the prevalence of GADA observed in normal control subjects (1.0 %).
In the 13 relatives who had ICA alone (1.1 % of the total population), ICA levels (15.8 ± 11.5 JDF-U) were significantly lower than in sera with one (30.2 ± 16.1 JDF-U, p < 0.005) or two additional markers (33.9 ± 14.6 JDF-U, p < 0.0005). A similar result was observed when GADA levels were compared between single GADA positive sera (31.3 ± 16.8 GAD-U) and sera with two or three autoantibodies (56.3 ± 28.2 GAD-U) (p < 0.03). Analysis of autoantibody levels in individual sera revealed a significant correlation between ICA and anti-IA-2 ic (r = 0.59, 95 % confidence interval: 0.44-0.70, p < 0.001) as well as ICA and GADA (r = 0.21, 95 % confidence interval: 0.01-0.39, p < 0.05). There was no correlation between the levels of anti-IA-2 ic and GADA (Fig. 3) . Data are n (%) Fig. 1 . Combinations of autoantibodies in 107 antibody positive first degree relatives of patients with IDDM. Antibodies to IA-2 ic (anti-IA-2 ic), antibodies to glutamic acid decarboxylase (GADA) and cytoplasmic islet cell antibodies (ICA) At initial screening (1, 14, 16 and 28 months before the development of IDDM) all prediabetic subjects were positive for ICA (40 JDF-U). In one child high levels of anti-IA-2 ic (163 IA-2-U) and GADA (36 GAD-U) were present; two children had high levels of anti-IA-2 ic (173 and 160 IA-2-U) but were negative for GADA (1.9 and 0.8 GAD-U) and one child was GADA positive (13 GAD-U) and anti-IA-2 ic negative (1.4 IA-2 U). All 4 prediabetic subjects were positive for either anti-IA-2 ic or GADA.
Discussion
In this study we assessed the value of antibodies to human recombinant IA-2 and GAD to identify subjects at increased risk for IDDM in a large population of first degree relatives of patients with IDDM. Since the short follow-up period does not allow accurate analysis of the predictive value of the antibodies, we compared anti-IA-2 ic and GADA with ICA which is the best validated serological marker found so far to estimate the risk for IDDM [1] [2] [3] [4] . We report here that combined screening for anti-IA-2 ic and GADA detected more than 93 % of subjects who possess a high risk for IDDM on the basis of high ICA titres, and all 4 individuals who subsequently developed overt IDDM during the follow-up period were positive for either anti-IA-2 ic or GADA. The use of 96-well radiobinding techniques to measure these antibodies allows rapid and quantitative screening for autoantibodies on a large scale, overcoming some of the limitations of the ICA test [5, 6] . Anti-IA-2 ic were found to be present in 4.4 % of the large cohort of 1238 first degree relatives which is a prevalence comparable with the frequencies of ICA or IAA reported from several family studies and is similar to the estimated cumulative incidence of IDDM in first degree relatives [1] [2] [3] 7] . We observed a strong association of anti-IA-2 ic with the presence of ICA confirming previous reports on antibodies to the 37 kDa/40kDa antigens [4, 10, 12, 21] . Thus, ICA were present in all but three sera with anti-IA-2 ic. Conversely, anti-IA-2 ic were found in 59.3 % of subjects with detectable ICA (L 3 JDF-U). The prevalence of anti-IA-2 ic in ICA positive subjects was higher than in previous studies where antibodies to the 37 kDa/40kDa antigens were detected in only 17 % of ICA positive first degree relatives [4, 21] . These studies are not strictly comparable because of differences in protocols for measurement of autoantibodies. The use of recombinant antigen in radioligand binding assays may increase the sensitivity of detection, as described for GADA [22] [23] [24] . Anti-IA-2 ic were detected in 3 of the 4 subjects who progressed to IDDM during a mean follow up period of 23 months. The high prevalence of anti-IA-2 ic in prediabetic and ICA positive relatives is consistent with previous reports which have described antibodies to the 40 kDa antigen in a high proportion of prediabetic relatives and ICA positive patients with recent-onset IDDM [4, 10, 11] . The segregation of anti-IA-2 ic positive relatives in a subgroup of ICA positive subjects with high risk for IDDM indicates Fig. 3 . A-C Relationship between autoantibody levels in first degree relatives of patients with IDDM. Levels of islet cell antibodies (ICA) were compared with levels of antibodies to IA-2 ic (anti-IA-2 ic) (A) and levels of antibodies to glutamic acid decarboxylase (GADA) (B). The levels of anti-IA-2 ic were correlated with levels of GADA (C). Anti-IA-2 ic and GADA levels are expressed in arbitrary units (AU) and ICA are given in JDF-U that these antibodies are valuable tools in the prediction of IDDM.
Although a large proportion of ICA positive subjects are identified by anti-IA-2 ic, primary screening for anti-IA-2 ic alone does not detect all the individuals at risk for IDDM. To improve sensitivity we combined anti-IA-2 ic with GADA which can be easily detected using recombinant antigen in the same assay format [25] . As for anti-IA-2 ic, GADA were positively associated with the presence of ICA, and in particular with high levels of ICA. These findings are in agreement with previous observations on a preferential occurrence of GADA in ICA positive prediabetic subjects and patients with IDDM [22, [25] [26] [27] . Positivity for GADA alone, in the absence of other antibody markers, which is known to be correlated with a low risk for IDDM [13, 14] , was observed in only 1.5 % of the total population. Although screening for GADA may identify individuals who are unlikely to develop IDDM, these are rare. It is important to note, however, that GADA identified 62.9 % of ICA positive subjects who were negative for anti-IA-2 ic. Risk estimation in several family studies revealed that the additional presence of GADA in sera of ICA positive first degree relatives indicates an increased risk for IDDM. Inclusion of GADA may thus complement anti-IA-2 ic in screening programmes and may increase sensitivity for prediction of IDDM [4, 12] . Despite a high correlation between GADA or anti-IA-2 with ICA 13 (1.05 % of the study population) individuals were found exclusively ICA positive. Of those 13 subjects 9 (69.2 %) had ICA levels of less than 10 JDF-U indicating that only a small number of subjects who may progress to overt IDDM might be missed by the combined screening of anti-IA-2 ic and GADA.
In conclusion, the use of human recombinant autoantigens IA-2 and GAD made it possible to develop radiobinding assays which allow rapid and sensitive detection of two major targets of humoral autoimmunity in IDDM. Our findings indicate that the combination of anti-IA-2 ic and GADA can accurately identify subjects at risk for IDDM identified on the basis of ICA positivity. The present approach offers an alternative strategy which might possess the power to replace ICA for primary screening in large-scale population studies. At present the use of both anti-IA-2 ic and GADA is limited by the still unknown predictive values of both markers which need to be validated in prospective family studies and the general population. Accurate risk estimation, however, can be achieved by a two-step procedure whereby initial combined screening for GADA and anti-IA-2 ic is followed by scoring of ICA in those subjects positive for one marker. This strategy may considerably facilitate population-based screening programmes to identify subjects for intervention trials to prevent the development of IDDM.
